Früh M et al. – Adjuvant cisplatin-based chemotherapy should not be withheld from elderly pt with non–small-cell lung cancer (NSCLC) purely on the basis of age Methods
Pooled analysis to assess efficacy and toxicity of adjuvant cisplatin-based chemotherapy in elderly pts with NSCLC
Review of individual patient data from 4,584 pts enrolled in 5 trials of cisplatin-based chemotherapy as the basis for the Lung Adjuvant Cisplatin Analysis (LACE) pooled analysis
Comparison of pt and treatment characteristics, overall and event-free survival, cause-specific mortality, chemotherapy toxicity and delivery among 3 age grps
Age grps: young (<65 yrs) pts: 3,269 (71%); midcategory (65-69): 901 (20%); elderly ≥70) 414 (9%)
Log-rank tests stratified by trials used with a test for trend to study chemotherapy effects on survival according to age
Results
Hazard ratio (HR) of death: 0.86 for young, 1.01 for mid, 0.90 for elderly pts
HR for event-free survival: 0.82 for young, 0.90 for mid, 0.87 for elderly pts
More elderly pts died from non–lung cancer–related causes (12% young, 19% mid, 22% elderly)
No differences in severe toxicity rates
Elderly pts had significantly lower first and total cisplatin doses and fewer chemotherapy cycles
See all
